Neural Noise

Synchron

3 min read

  • Synchron’s Stentrode BCI device demonstrated first clinical use for communication restoration in ALS patients (April 2025).1
  • Synchron featured prominently in BCI industry coverage as a minimally invasive option, competing with Neuralink.12 12

Gardner updates

  • Synchron raised $75M in Series C financing, validating the endovascular BCI approach.3

  • Synchron’s fundraise accelerates the endovascular BCI pathway and is a significant industry signal for next-generation implant strategy.3

  • Synchron expanded its clinical trial program, advancing toward broader access for patients.4

  • Microsoft and Synchron have partnered for a direct neural interface to Microsoft products. 5

Weekly enrichment (2026-07-20)

  • Synchron’s COMMAND early feasibility study — described as the first FDA-approved investigational device exemption (IDE) trial of a permanently implanted BCI — enrolled six patients with severe chronic bilateral upper-limb paralysis and reported positive 12-month results, meeting its primary safety endpoint with no device-related serious adverse events causing death or permanent disability.67
  • COMMAND was conducted across three U.S. sites — Mount Sinai Health System (New York City), UB Neurosurgery/Gates Vascular Institute, and UPMC in collaboration with Carnegie Mellon University — with support from the NIH BRAIN Initiative.6
  • The Stentrode is a self-expanding nitinol stent roughly 40 mm long carrying 16 platinum electrodes spaced about 3 mm apart, delivered transvenously through the jugular vein into the superior sagittal sinus adjacent to the motor cortex in an approximately 20-30 minute procedure under conscious sedation, avoiding craniotomy.8
  • An exploratory analysis of chronically implanted Stentrode recordings in the six COMMAND participants tracked motor signal strength, resting-state features, and electrode impedance for up to 12 months, supporting long-term endovascular signal stability.9
  • Synchron raised a $200 million Series D announced November 6, 2025 to fund a 2026 pivotal trial and prepare its first-generation device for commercial launch; the Stentrode has held FDA Breakthrough Device designation since August 2020.107
  • The company says it must clear the 2026 pivotal trial before filing for FDA premarket approval (PMA), which would be the first PMA for an implantable BCI; CEO Tom Oxley has described ramping manufacturing to enroll roughly 30-50 participants.1011
  • In August 2025 an ALS patient used the Stentrode to natively control an Apple iPad — navigating apps and composing texts by thought — reported as the first BCI to natively control an Apple device; Synchron also opened a San Diego engineering hub for a next-generation high-channel implant.7
  • At NVIDIA’s GPU Technology Conference in March 2025, Synchron unveiled Chiral, a “cognitive AI” brain foundation model trained via self-supervised/generative pre-training on roughly 20 patient-years of neural data collected since its clinical program began in 2019.11
  • Synchron’s January 2025 collaboration with NVIDIA builds the BCI on the NVIDIA Holoscan platform for real-time on-device edge processing, aiming to lower system latency and improve the responsiveness of motor decoding.12

Footnotes

  1. https://news.google.com/rss/articles/CBMiWkFVX3lxTE5VcGhPM0pzdE5IMVFraVhWaVliRmM1a0Z5ZU16Y2VrTjI5dzZQeVY3NFJtN2RpVmNWY25ZZEhJZEk1cVFJaWFzanl2bXFhS1M0MlVGS25JNFpn?oc=5 ↩ ↩2 ↩3

  2. https://news.google.com/rss/articles/CBMiuAFBVV95cUxNV1hLMkMwdGFiNU9SWWxTanNVZTN3UVNheVZadmszZGtVZW1xWkl0Ynl1cnk5S1RxMldSeVVGbHFJUFZYc3B0dkx6Z05ZdzBOdzlLaVNmM25TRWY4ZzNlNXZLcnJEX3M2bVNPd0lPV3J2TjlIb2VHOHpLb2dRS1VuTjdRRGlFa0UwT0U2VkNKVkgwQ2hhQzFPOVMzUUpiMlVsQnpSUjFPWVBIZlBKNi1HTW9EUHRpeg?oc=5 ↩ ↩2

  3. https://news.google.com/rss/articles/CBMingFBVV95cUxPcVdKYWlxTWFBUzdLcHBSN01wWEdDREJxUU1Db0RnWVkyd0RnNEppUE9aTUk4ZWZobzd0Sl9hU1d4a1dGNWFBa1RYWXZUTmlSaFJneGt6X0Y3bnR1QjlIbjNjRVhCeHY3UGhJdUdYYTM2QW5VWFBIUlhaTXZXQXV3bFVqVWVXeThKcGtHY1VkTlF4NjJBcWRlMW0tV2lnb3ZjeGl3?oc=5 ↩ ↩2

  4. https://news.google.com/rss/articles/CBMijgFBVV95cUxOTUNOazZnclc0d3BQNm5Dd3Y3eXFpM01hV0V2VFNKd0VVazN1dFhvcTZuUXNtRWdaRHNQZGJSM0FsOE9SMnRxZEJIY2hXV044SVdkM2J2d0pMWVhDNFJJOGxMWGFXb1Z6RVVuYjU4bHdocmZnVVlDZjZlNFdweVg0b1E5RFVlTloxQ3RWSDE4?oc=5 ↩

  5. https://news.google.com/rss/articles/CBMixAFBVV95cUxNUVR5NGc4UGxNYzgteUcyZjRNOUw1cXlFZDB1aTdvLW1kZ3BmdmhBYTAyR3JKbW1Cb0NxNE11X1RWalJqNkVmVFBCUDBRSi1QeHJuU25FMldLZ3l4WXJMYW5sN0NOR0VRclUwMFpJV09US1ZDYzFweElMMDFQd0VQcEJnc2hyZzdYS1BhZkZjV1BQRC10VUg3bXZPUVgzLUkyU3BhQzFJQXlyMVJubm1IeUx2TkxHRGJWemNveDJkRGFIVm5jMDR3OUFnekFXdWg0WFkzWHpz?oc=5 ↩

  6. https://www.businesswire.com/news/home/20240930433219/en/Synchron-Announces-Positive-Results-from-U.S.-COMMAND-Study-of-Endovascular-Brain-Computer-Interface ↩ ↩2

  7. https://time.com/collection/time100-most-influential-companies/2026/synchron/ ↩ ↩2 ↩3

  8. https://www.neurofounders.co/articles/how-does-synchrons-brain-computer-interface-work ↩

  9. https://www.medrxiv.org/content/10.1101/2025.09.19.25335897v1.full.pdf ↩

  10. https://www.techtimes.com/articles/317929/20260606/synchron-brain-implant-targets-2026-pivotal-trial-first-fda-approved-bci.htm ↩ ↩2

  11. https://www.businesswire.com/news/home/20250319964709/en/Synchron-Unveils-Chiral-the-Worlds-First-Cognitive-AI-Brain-Foundation-Model ↩ ↩2

  12. https://www.businesswire.com/news/home/20250113376337/en/Synchron-to-Advance-Implantable-Brain-Computer-Interface-Technology-with-NVIDIA-Holoscan ↩

Graph View